Schedule 13G ownership disclosure

Compass Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 20454B104

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TANG CAPITAL MANAGEMENT, LLC

    Shares: 13,496,208.00 · Class: 9.8%

  • KEVIN TANG

    Shares: 13,496,208.00 · Class: 9.8%

  • TANG CAPITAL PARTNERS, LP

    Shares: 6,765,438.00 · Class: 4.9%

  • TANG CAPITAL PARTNERS INTERNATIONAL, LP

    Shares: 5,397,770.00 · Class: 3.9%

  • TANG CAPITAL PARTNERS III, INC

    Shares: 999,750.00 · Class: 0.7%

  • TANG CAPITAL PARTNERS IV, INC

    Shares: 333,250.00 · Class: 0.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001214659-25-012266
Form type
SCHEDULE 13G/A
Filer
Compass Therapeutics, Inc.
CIK
CIK 1738021
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub